T-Guard is emerging as a safe and effective tool to swiftly remove mature T cells, enabling the immune system to ‘reset’ with healthy, replacement cells, with minimal side-effects. While current registration procedures are initially targeted at T-Guard’s use in the treatment of acute GVHD, there is absolutely no reason why its use should be restricted to this. The medicine could have great promise in treating several other diseases involving hyperactive, misdirected, or malignant T cells, such as solid organ rejection, autoimmune diseases and T cell derived blood cancers.
Solid organ rejection
This is another widespread medical procedure for replacing malfunctioning organs of an increasing range. Lifelong treatment with immunosuppressive drugs is usually required to help the patient’s body accept the transplanted tissue, but despite this precaution, acute rejection can still occur. T-Guard may provide an attractive alternative to other experimental drugs used in this incidence base on its better tolerability and faster action.
Current medications for the wide range of auto-immune diseases that exist are typically directed at limiting symptoms and managing pain, rather than curing the condition. The long-term use of many of them can cause significant side-effects. Autoreactive T cells play a crucial role. A relatively new treatment strategy is to reset the body’s immune system through self- or donor-derived blood stem cell transplant. This is a complex process that is frequently associated with serious side effects. T-Guard might provide a milder, more specific alternative applicable to a wider patient group.
T Cell Derived Blood Cancers
T-Guard might also be used to kill malignant T cells. Pre-clinical research with well –known hemato-oncology centers has already been scheduled to investigate the potential of the medicine in this further.